Tennor Therapeutics Ltd., of Suzhou, China, has completed a $25 million series B financing led by Northern Light Venture Capital with current investors Frontline Bioventures, Wuxi Pharmatech Healthcare Fund I, Oriza Venture Capital and Relativity Healthcare Fund also joining the round. The company is focused on the development of dual-acting antibiotics with most advanced product, TNP-2092 oral capsule, a locally acting gastrointestinal tract antibiotic. The funding will be used to advance TNP-2092 oral capsule into phase III trials, as well as move a second product into the clinical proof-of-concept stage and a third product into phase I development.